STUDY PROTOCOL

REVISED The impact of city-wide deployment of *Wolbachia*-carrying mosquitoes on arboviral disease incidence in Medellín and Bello, Colombia: study protocol for an interrupted time-series analysis and a test-negative design study [version 2; peer review: 2 approved, 1 approved with reservations]

Ivan D. Velez¹, Eduardo Santacruz¹, Simon C. Kutcher², Sandra L. Duque ¹, Alexander Uribe¹, Jovany Barajas¹, Sandra Gonzalez¹, Ana Cristina Patino¹, Lina Zuluaga¹, Luis Martínez¹, Estefanía Muñoz ¹, María Camila Mejía¹, María Patricia Arbelaez¹, Henry Pulido³, Nicholas P. Jewell^{4,5}, Suzanne M Dufault ⁴, Scott L. O'Neill², Cameron P. Simmons², Katherine L. Anders ², Stephanie K. Tanamas²

¹World Mosquito Program, Universidad de Antioquia, Medellín, Colombia

²World Mosquito Program, Institute of Vector Borne Disease, Monash University, Melbourne, VIC, Australia

³Secretariat of Health, Bello, Colombia

⁴Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, CA, USA

⁵Centre for Statistical Methodology, London School of Hygiene & Tropical Medicine, London, UK

V2 First published: 01 Aug 2019, 8:1327
<https://doi.org/10.12688/f1000research.19858.1>
 Latest published: 21 May 2020, 8:1327
<https://doi.org/10.12688/f1000research.19858.2>

Abstract

Background: Dengue, chikungunya and Zika are viral infections transmitted by *Aedes aegypti* mosquitoes, and present major public health challenges in tropical regions. Traditional vector control methods have been ineffective at halting disease transmission. The World Mosquito Program has developed a novel approach to arbovirus control using *Ae. aegypti* stably transfected with the *Wolbachia* bacterium, which have significantly reduced ability to transmit dengue, Zika and chikungunya in laboratory experiments. Field releases in eight countries have demonstrated *Wolbachia* establishment in local *Ae. aegypti* populations.

Methods: We describe a pragmatic approach to measuring the epidemiological impact of city-wide *Wolbachia* deployments in Bello and Medellín, Colombia. First, an interrupted time-series analysis will

Open Peer Review

Approval Status

	1	2	3
version 2			
(revision)			
21 May 2020			
version 1			
01 Aug 2019			

1. **Stephen Waterman**, Centers for Disease Control and Prevention (CDC), San Juan, Puerto Rico

compare the incidence of dengue, chikungunya and Zika case notifications before and after *Wolbachia* releases, across the two municipalities. Second, a prospective case-control study using a test-negative design will be conducted in one quadrant of Medellín. Three of the six contiguous release zones in the case-control area were allocated to receive the first *Wolbachia* deployments in the city and three to be treated last, approximating a parallel two-arm trial for the >12-month period during which *Wolbachia* exposure remains discordant. Allocation, although non-random, aimed to maximise balance between arms in historical dengue incidence and demographics. Arboviral disease cases and arbovirus-negative controls will be enrolled concurrently from febrile patients presenting to primary care, with case/control status classified retrospectively following laboratory diagnostic testing. Intervention effect is estimated from an aggregate odds ratio comparing *Wolbachia*-exposure odds among test-positive cases versus test-negative controls.

Discussion: The study findings will add to an accumulating body of evidence from global field sites on the efficacy of the *Wolbachia* method in reducing arboviral disease incidence, and can inform decisions on wider public health implementation of this intervention in the Americas and beyond.

Trial registration: ClinicalTrials.gov: [NCT03631719](#). Registered on 15 August 2018.

Keywords

Wolbachia, dengue, chikungunya, Zika, vector-borne disease, disease surveillance, interrupted time series, Colombia

This article is included in the [Emerging Diseases and Outbreaks](#) gateway.

This article is included in the [Neglected Tropical Diseases](#) collection.

Roberto Barrera, Centers for Disease Control and Prevention (CDC), San Juan, Puerto Rico

2. **Penelope Hancock**, University of Oxford, Oxford, UK

3. **Amy Morrison** , University of California, Davis (UC Davis), Davis, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Katherine L. Anders (katie.anders@worldmosquito.org)

Author roles: **Velez ID:** Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Writing – Review & Editing; **Santacruz E:** Conceptualization, Investigation, Project Administration, Writing – Original Draft Preparation; **Kutcher SC:** Conceptualization, Project Administration, Writing – Review & Editing; **Duque SL:** Investigation, Project Administration, Writing – Review & Editing; **Uribe A:** Investigation, Writing – Review & Editing; **Barajas J:** Investigation, Writing – Review & Editing; **Gonzalez S:** Investigation, Writing – Review & Editing; **Patino AC:** Investigation, Writing – Review & Editing; **Zuluaga L:** Data Curation, Investigation, Writing – Review & Editing; **Martínez L:** Data Curation, Investigation, Writing – Review & Editing; **Muñoz E:** Data Curation, Investigation; **Mejia MC:** Investigation, Writing – Review & Editing; **Arbelaez MP:** Investigation, Project Administration, Writing – Review & Editing; **Pulido H:** Investigation, Resources, Writing – Review & Editing; **Jewell NP:** Conceptualization, Formal Analysis, Methodology, Writing – Review & Editing; **Dufault SM:** Methodology, Writing – Review & Editing; **O'Neill SL:** Conceptualization, Funding Acquisition, Writing – Review & Editing; **Simmons CP:** Conceptualization, Methodology, Writing – Review & Editing; **Anders KL:** Conceptualization, Methodology, Writing – Original Draft Preparation; **Tanamas SK:** Conceptualization, Methodology, Writing – Original Draft Preparation

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust working in partnership with the UK Department for International Development (Grant 102591/Z/13/A), United States Agency for International Development (Grant AID-OAA-AA-16-00081), and Bill & Melinda Gates Foundation (Grant OPP1159497).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Velez ID *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Velez ID, Santacruz E, Kutcher SC *et al.* **The impact of city-wide deployment of *Wolbachia*-carrying mosquitoes on arboviral disease incidence in Medellín and Bello, Colombia: study protocol for an interrupted time-series analysis and a test-negative design study [version 2; peer review: 2 approved, 1 approved with reservations]** F1000Research 2020, 8:1327 <https://doi.org/10.12688/f1000research.19858.2>

First published: 01 Aug 2019, 8:1327 <https://doi.org/10.12688/f1000research.19858.1>

REVISED Amendments from Version 1

Information on the historical annual average incidence of dengue in Medellín and Bello has been added to the background section. Minor clarifications have been made to the descriptions of *Wolbachia* deployment and monitoring methods. A case definition for the severe dengue secondary endpoint of the interrupted time series analysis has been included. Additional detail has been provided on the statistical methods for the ITS analysis. The study timeline has been removed to reflect an extension to the case-control study period in order to attain the target sample size, given a lower than expected initial event rate. An additional per-protocol analysis for the case-control study has been added. A discussion has been added of the potential for spillover effects from an interruption of dengue transmission in the case-control early release zone, into adjacent untreated areas.

Any further responses from the reviewers can be found at the end of the article

Abbreviations

BG trap: BioGents Sentinel trap; CI: cytoplasmic incompatibility; ELISA: enzyme-linked immunosorbent assay; IRB: Institutional Review Board; PECET: Programa de Estudio y Control de Enfermedades Tropicales; qPCR: qualitative polymerase chain reaction; SAE: serious adverse event; WEI: *Wolbachia* exposure index; WHO: World Health Organisation; wMel: *Wolbachia pipiensis*; WMP: World Mosquito Program

Background

Dengue is a major public health challenge in tropical regions, with 50 – 100 million symptomatic cases estimated to occur each year^{1,2}. The World Health Organisation (WHO) cites a 30-fold increase in global incidence during the past 50 years¹, and among endemic regions the greatest relative increase in dengue disease burden over the past two decades has been seen in Latin America². The primary vector for dengue, the *Aedes aegypti* mosquito, also transmits the chikungunya and Zika viruses. Chikungunya emerged in epidemic fashion in several Indian Ocean islands in 2004 before spreading to southern Europe and South and South East Asia, then in 2013 re-emerged in epidemics in the Caribbean and several Latin American countries³. Following Zika virus outbreaks in the Western Pacific in 2013 and in Latin America in 2015⁴, it was declared a public health emergency of international concern by the WHO in 2016⁵ as evidence accumulated that congenital Zika virus infections can result in severe outcomes including foetal death and severe microcephaly. No specific treatment for dengue, chikungunya or Zika currently exists. Although a vaccine against dengue (Sanofi Dengvaxia[®]) was licensed in 2015, the WHO recommends vaccination only in persons with proven past dengue infection^{6,7}. While efforts to develop a safe and effective vaccine continue, the WHO has emphasised the need for innovations in vector control to achieve reductions in dengue virus transmission and disease burden⁸. The evidence base for the effectiveness of commonly used vector control interventions is limited, with few having been rigorously evaluated against a clinical disease endpoint⁹. This highlights a vital need for carefully designed studies to evaluate vector control methods for arboviral and other vector-borne diseases¹⁰.

The World Mosquito Program (WMP; formerly the Eliminate Dengue Program) is an international research collaboration that is delivering a paradigm shift in the control of arboviral diseases transmitted by *Ae. aegypti* mosquitoes. Our method utilises *Wolbachia*, obligate intracellular endosymbionts that are common in insect species^{11–14} but were not present in *Ae. aegypti* mosquitoes until they were stably transinfected in the laboratory. In insects, *Wolbachia* is maternally inherited and manipulates insect reproduction to favour its own population dissemination via cytoplasmic incompatibility (CI). Strikingly, the presence of *Wolbachia* in *Ae. aegypti* mosquitoes reduces their ability to transmit viruses including dengue, Zika, chikungunya, and yellow fever^{15–17}. Introgression of *Wolbachia* into wild *Ae. aegypti* populations is thus expected to severely reduce the vectorial capacity of local mosquito populations to transmit these arboviral infections. WMP's field teams release male and female *Wolbachia*-infected *Ae. aegypti* as eggs or adults over a number of weeks. These mosquitoes then breed with the wild mosquito population and over time, through the actions of CI, the prevalence of *Wolbachia* in the local mosquito population increases, until such time as the majority of mosquitoes in the area carry *Wolbachia*. The WMP has demonstrated reduced vector competence in *Wolbachia*-infected mosquitoes obtained from the field, using human dengue viremic blood and a novel read-out to measure infectious mosquito saliva¹⁸. *Wolbachia* viral interference effects were found for all four DENV serotypes, resulting in estimated reductions of 66–75% in the basic reproduction number R_0 for DENV-1-4. Reductions of this magnitude are predicted to result in local elimination of DENV transmission in most epidemiological settings¹⁸.

Colombia, located in the northwestern region of South America, is home to one-tenth of the population of Latin America. The *Ae. aegypti* mosquito is highly prevalent and dengue is endemic. In 2010 Colombia recorded its largest dengue outbreak with more than 150,000 confirmed cases, 217 deaths, and simultaneous circulation of all four dengue serotypes¹⁹. The first autochthonous chikungunya case was detected in Colombia in September 2014^{20,21} and the first case of Zika in October 2015²². Since then, numerous cases of both have been reported in the country.

The protocol presented in the current paper describes a pragmatic approach to measuring the efficacy of large-scale *Wolbachia* deployments in reducing the burden of arboviral diseases, in the municipalities of Medellín and Bello in northwestern Colombia, which have urban populations of 2.2 million in an area of ~100km² and 476,000 in ~20km², respectively. The mean annual incidence of notified dengue cases in the seven years 2010–2016 prior to the start of scaled *Wolbachia* deployments was 298 per 100,000 population in Medellín (range 38 – 771 per 100,000) and 188 per 100,000 population in Bello (range 36 – 446 per 100,000). The mean annual incidence of notified dengue cases in the seven years 2010–2016 prior to the start of scaled *Wolbachia* deployments was 298 per 100,000 population in Medellín (range 38 – 771 per 100,000) and 188 per 100,000 population in Bello (range 36 – 446 per 100,000). Staged deployment at the city-wide scale and within a relatively short time frame was favoured over a randomised controlled

trial or other randomised design both by funders and local stakeholders. This was driven by what was, at the time of project conception, an urgent need for novel scalable strategies to combat the threat of Zika, and also a desire for the flexibility to optimise methods for scaled deployment under operational conditions, rather than the more restrictive implementation required for a formal randomised controlled trial. The proposed strategy for evaluating the impact of these staged deployments on the incidence of arboviral disease is a combination of an interrupted time-series analysis of notified arboviral disease incidence in all of Medellín and Bello, together with a more rigorous test-negative design study implemented in a sub-section of the Medellín municipal area. The primary aim of the study is to investigate whether large-scale deployments of *Wolbachia*-infected *Ae. aegypti* mosquitoes in Medellín and Bello, Colombia, lead to a measurable reduction in arboviral disease incidence.

Methods

Two complementary approaches will be used to evaluate the disease impact of *Wolbachia* releases in Medellín and Bello:

- i. An interrupted time-series analysis utilising routine disease surveillance data collected by the Medellín and Bello Health Secretariats, which aims to compare incidence of dengue, chikungunya and Zika pre- and post-*Wolbachia* release. This analysis will be applied separately to Medellín and Bello.
- ii. A prospective case control study using a test-negative design, which aims to quantify the reduction in disease incidence among people living within a *Wolbachia*-treated zone compared with an untreated zone that has a similar dengue risk profile at baseline. This study will be conducted in only one quadrant of Medellín (Figure 1).

Wolbachia deployment

Wolbachia-containing adult *Ae. aegypti* mosquitoes and eggs will be deployed sequentially through the study area, starting with the early-release zone of the case-control study (yellow shading in Figure 1; produced in ArcMap version 10.5, ESRI, CA),

Figure 1. Deployment of *Wolbachia* across Medellín and Bello, combining pragmatic staged deployment (light green and blue) with a test-negative design study in a focused study area of ‘early’ (yellow) and ‘late’ (dark green) release zones (produced in ArcMap version 10.5, ESRI, CA).

followed by releases in parts of Medellín and Bello outside the case-control area (light green and blue shading in [Figure 1](#)), then lastly in the late-release area of the case-control study (dark green shading in [Figure 1](#)). For the purpose of analysis, release zones will be considered *Wolbachia*-treated from the date of completion of releases.

An initial period of *Wolbachia* deployment was undertaken in the early-release zone of the case-control area and in parts of Bello between April and December 2017, resulting initially in a high prevalence of *Wolbachia*. However, *Wolbachia* levels declined after cessation of releases. We believe this was due to fitness issues with the *Wolbachia*-infected mosquitoes, specifically that they were less resistant to insecticides than the wild population. Insectary processes were subsequently updated and a new colony of *Wolbachia* mosquitoes was produced that matched the wild-type insecticide resistance profile. Subsequent rounds of deployments were then conducted in these areas between mid-2018 and late-2019. It is this deployment period that will be considered for the purpose of the analyses described in this protocol.

Wolbachia monitoring strategy

Wolbachia prevalence is monitored through a network of BG-Sentinel adult mosquito traps (BioGents) that are evenly spaced throughout all of Bello and Medellín, including the case-control study area at a density of approximately 16 BG traps per km². BG traps are serviced weekly, with trapped mosquitoes screened for *Wolbachia* at weekly, fortnightly or monthly intervals throughout the duration of the study, depending on the stage of release and establishment. BG traps that do not catch any mosquitoes in three consecutive weeks are moved to another location. Trapped mosquitoes will be identified using microscopy. Individual *Ae. aegypti* mosquitoes (male and female) will be tested for *Wolbachia* by quantitative polymerase chain reaction (qPCR) assay. The *Wolbachia* prevalence in screened *Ae. aegypti* will be reported aggregated to the zone (i.e. early- and late-release zone in case-control area) or commune (for parts of the city outside of the case-control area) level, calculated as the total number of *Ae. aegypti* mosquitoes that tested positive for *Wolbachia* aggregated across all BG traps in the zone/commune, divided by the total number of *Ae. aegypti* mosquitoes that were screened in that zone/commune.

Epidemiological study 1: Interrupted time-series analysis using notifiable disease surveillance data

Notifiable disease surveillance data. In Medellín and Bello, routine public health surveillance for dengue is passive. There are more than 400 public and private health institutions that routinely report clinically-suspected and laboratory-confirmed dengue cases to the Secretary of Health as part of the Epidemiological Surveillance System. Approximately 10% of clinically-suspected dengue cases from hyperendemic or epidemic territories in Colombia are laboratory tested, however this proportion varies and was as high as >60% in 2016 in Medellín. Laboratory evidence suggestive of dengue is usually acquired via detection of anti-dengue IgM antibodies. Laboratory testing for chikungunya

and Zika is not routinely performed in Colombia and is only done to demonstrate viral circulation in the area rather than for diagnostic purposes.

For the interrupted time-series analysis, disaggregate (line-listed) data will be requested for notified (clinically-suspected) dengue, chikungunya and Zika cases, and also the subset of dengue cases with IgM ELISA test results, from 2009 to 2025 for both Medellín and Bello. The dataset will include age, sex, address of primary residence, date of illness onset, date of notification, reporting health clinic, disease severity, hospitalisation, death, and, where available, geo-coordinates of the primary residence, type of diagnostic test performed, diagnostic test result, and final diagnostic classification.

Primary and secondary endpoints. The primary endpoint is the incidence of all dengue case notifications to the Epidemiological Surveillance System.

The secondary endpoints are: i) the number of cases who were IgM test positive for dengue; ii) the incidence of severe dengue cases reported to the surveillance system; and iii) the incidence of Zika and chikungunya cases reported to the surveillance system.

Severe dengue is defined as any case of dengue that has one or more of the following manifestations: i) shock or respiratory distress due to severe plasma leakage; ii) severe bleeding according to the evaluation of the treating physician; or iii) severe organ involvement, such as liver damage, impaired consciousness, myocarditis, or other organ involvement.

Statistical analysis. For the primary endpoint and secondary endpoints above, the impact of *Wolbachia* deployment on disease incidence will be evaluated using an interrupted time series analysis of arbovirus cases reported to the Epidemiological Surveillance System before and after *Wolbachia* establishment. A generalised estimating equation (GEE) approach will be used to model monthly case counts as the outcome variable, with an offset for population size and controlling for seasonality and inter-annual variation using flexible cubic splines or polynomial functions. The outcome distribution is assumed to be negative binomial to allow for overdispersion. The *Wolbachia* intervention effect will be modelled firstly as a binary predictor comparing dengue incidence pre- vs post-intervention to estimate the level change in incidence following the *Wolbachia* intervention. An additional analysis will consider *Wolbachia* frequency as a continuous covariate or categorised into quintiles of exposure reflecting the measured *Wolbachia* prevalence in the local mosquito population. Robust standard errors will be used to account for clustering of cases by commune. An autoregressive correlation structure will be specified to account for temporal autocorrelation. This analysis will be done separately for Medellín and Bello, 12 months after the completion of releases and each 12 months thereafter until five years post-intervention. The staged nature of releases across communes allow the pre-intervention period in each commune to serve as a contemporaneous untreated comparator for the treated communes, in

a simple uncontrolled ITS analysis, until all communes are *Wolbachia*-treated. A controlled ITS analysis will also be undertaken, using other Colombian municipalities with synchronous historical dengue time series as an untreated comparator.

There is a possibility that the inference estimation of the GEE approach is affected by the modest number of clusters (18 in Medellín and 11 in Bello) each with a large number of observations. A mixed-effects negative binomial model will be used to check for small sample size issues in inference estimation. A difference in estimates between the GEE approach and mixed-effects model suggests small sample size could be a biasing factor, and depending on the direction of the discrepancy, may be related to a tendency towards inflated Type 1 error rates when using the GEE technique with small cluster numbers or inappropriate modelling assumptions in the mixed-effects model. Additional follow-up analyses may be required.

Epidemiological study 2: Prospective case control study

Study design. The prospective clinic-based case control study uses a test-negative design. The impact of *Wolbachia* deployments on arboviral disease incidence will be assessed by comparing the exposure distribution (probability of living in a *Wolbachia*-treated (early-release) vs. untreated (late-release) area) among virologically-confirmed arboviral disease cases presenting to a network of primary healthcare clinics, against the exposure distribution among patients with febrile illness of non-arboviral aetiology presenting to the same network of clinics in the same temporal window. Arboviral disease cases and arbovirus-negative controls will be sampled concurrently from within the population of patients who reside in the case-control area and present with febrile illness to the study clinic network, with case or control status classified retrospectively based on the results of laboratory diagnostic testing. The distribution of *Wolbachia* exposure in the sampled arbovirus negative controls is assumed to reflect the distribution of *Wolbachia* exposure in the underlying source population that gave rise to cases, as long as a core assumption is met that the relative propensity to seek healthcare for febrile illness at the study clinics in early-versus late-release arms is the same for arboviral disease cases as other febrile illness controls. This should be upheld if cases and controls are clinically indistinguishable until laboratory diagnosis. The concurrent sampling of cases and controls means that the odds of *Wolbachia*-exposure among sampled

arboviral disease cases relative to febrile controls (i.e. odds ratio), is an unbiased estimate of the relative incidence of medically-attended arboviral disease in *Wolbachia* early-release versus late-release areas (i.e. relative risk or incidence rate ratio), from which protective efficacy can be estimated directly.

Study setting. The case-control study will be conducted only within a focused study area in northeast Medellín, including six contiguous release zones within four communes (Figure 1), with a total population of 580,000 and area 15km². Among these six release zones, three have been allocated non-randomly as the first zones in Medellín to receive *Wolbachia* deployments (early-release), and three as the last (late-release), such that a parallel two-arm trial is approximated for the period during which *Wolbachia* exposure remains discordant between arms. There are no buffer areas between treatment arms, but natural borders (roads, rivers, non-residential areas) were used to define study arm boundaries as much as possible, to limit the spatial spread of *Wolbachia* from treated areas into untreated areas, and of wild-type mosquitoes into *Wolbachia* treated areas. No attempt will be made to alter the routine dengue prevention and vector control activities conducted by public and private agencies throughout the case-control study area.

Allocation of the intervention. The allocation of the six zones into two arms was done in a way that maximises balance between the arms with respect to measured factors that may be associated with baseline dengue risk, including historical dengue incidence, population characteristics, and geographical area (Table 1).

Study participants. Participants will be invited to participate, by trained research staff, from within the population of patients presenting with undifferentiated fever to a network of primary health care facilities that serve the population who reside in the study area. Participants (or their guardian if <18 years) must provide written informed consent, and meet the following inclusion criteria to be eligible for the study: fever (either self-reported or objectively measured as $\geq 38^{\circ}\text{C}$), with a date of onset between 1–4 days prior to the day of presentation to the health care facility; aged ≥ 3 years old; and lived (i.e. slept) in the study area for the 10 days preceding illness onset. Participants will not be eligible for inclusion if localizing features suggestive of a specific diagnosis (e.g. severe diarrhoea, otitis, pneumonia)

Table 1. Allocation of the six release zones into 'early' and 'late' release arms, maximizing balance between the two arms in baseline factors that may predict dengue risk.

'Early' Arm	'Late' Arm	Ratio of baseline characteristics in late/early arms (Ratio of 1 is perfectly balanced)				
		Aggregate dengue incidence 2013–2016	Population	Area	% population <15 years	Socio-economic status
Aranjuez A, Manrique A, Santa Cruz	Aranjuez B, Manrique B, Popular	1.18	1.02	1.20	1.00	1.11

are identified. An individual presenting to the clinic on repeat occasions for different febrile episodes will be eligible for enrolment during each different episode. However, an individual may only be enrolled once during a single illness episode, which is defined as illness occurring within 4 weeks of a previous febrile episode.

Data and sample collection. A unique identifier will be assigned to each participant at enrolment. Basic demographic details, eligibility against the inclusion criteria, illness onset date, and a retrospective travel history will be recorded in a standardised electronic data collection form. [Figure 2](#) summarises the data and sample to be collected from each participant.

A brief travel history interview will be conducted at enrolment to determine the main places visited by each participant within the 3–10 days prior to illness onset, i.e. the incubation period for dengue. The duration of time spent at home, work or school, and other visited locations during the hours of 5am to 9pm in the 8-day period will be recorded, and the geographic coordinates of those locations derived by geo-locating them on a digital map, with the assistance of the study participant. These data will be used to determine the proportion of time spent in *Wolbachia* treated and untreated areas, for the per-protocol analysis.

A single 6 ml venous blood sample will be collected from all consenting participants on the day of enrolment. Blood samples from all participants will be transferred to the project laboratory on the day of collection and batch-tested within one month to determine case or control status ([Figure 3](#)).

Laboratory investigations. An internally controlled triplex RT-qPCR assay (Bio-Rad) will be used to detect dengue, chikungunya and Zika viruses in serum samples from all enrolled

participants. Dengue NS1 ELISA (Dengue Early ELISA, Panbio) will be performed according to the manufacturer's instructions, on serum samples which have tested negative by DENV RT-qPCR. Dengue IgM and IgG capture ELISA (IgM/IgG Capture ELISA, Panbio) will be performed on serum samples which have tested negative by DENV RT-qPCR and NS1, and would otherwise be classified as controls, to determine whether they have detectable dengue IgM or IgG antibodies indicating potentially acute secondary dengue or another cross-reactive flavivirus infection in order to prevent misclassification. The IgG capture ELISA is designed with cutoffs to detect only high IgG titers consistent with acute secondary dengue (or cross-reactive flavivirus) infections, not past dengue virus infections. All research diagnostic investigations will be performed by the Programa de Estudio y Control de Enfermedades Tropicales (PECET), at the University of Antioquia, Colombia.

Case and control classification. Dengue cases are defined as patients with virologically-confirmed DENV infection, meeting the clinical criteria for enrolment and also with a positive result in NS1 ELISA or DENV RT-qPCR. Controls are patients meeting the clinical criteria for enrolment, but with negative test results for DENV RT-qPCR, CHIKV RT-qPCR, ZIKV RT-qPCR, DENV NS1 ELISA, and DENV IgM and IgG ELISA ([Figure 3](#)).

For the secondary endpoints, Zika or chikungunya cases are defined as patients with virologically-confirmed Zika or chikungunya infections, meeting the clinical criteria for enrolment and with a positive result in ZIKV RT-qPCR or CHIKV RT-qPCR, respectively, and controls are defined as above.

Expected study duration. Pilot clinic-based sampling of febrile patients commenced in November 2017, with enrolment into the intention-to-treat dataset after completion of *Wolbachia* releases in the early-release area. The study will continue to

	Prior to start of clinical study	Enrolment	1-30 days post-enrolment	>12 months after <i>Wolbachia</i> establishment in early-release area
INTERVENTION				
Deployment of <i>Wolbachia</i> mosquitoes in early-release area*	x			
Deployment of <i>Wolbachia</i> mosquitoes in late-release area*				x
ENROLMENT AT CLINICS				
Screen for eligibility		x		
Informed consent		x		
Enrolment form completed (electronic data capture)		x		
• Demographic data (name, sex, date of birth, address, contact number)				
• Illness history data (symptoms, date of illness onset)				
Travel history interview (electronic data capture)		x		
• Home and other places visited 3-10 days prior to illness onset including duration and geolocation				
6ml venous blood sample		x		
ASSESSMENTS				
Laboratory diagnostic testing for DENV, CHIKV, ZIKV			x	

Figure 2. Schedule of enrolment, data collection and assessments (SPIRIT Figure). *Routine dengue prevention and vector control activities will not be altered in treated or untreated areas. DENV: dengue virus; CHIKV: chikungunya virus; ZIKV: Zika virus.

Figure 3. Flowchart of data and sample collection procedures and diagnostic algorithm. Blue boxes indicate participant recruitment and enrolment activities undertaken at clinics. Yellow boxes indicate the laboratory diagnostic testing to be performed at the project laboratory, the results of which (white boxes) will be used to classify participants (grey boxes) as virologically confirmed dengue, Zika or chikungunya cases, arbovirus-negative controls, or excluded due to inability to rule out arbovirus infection according to the algorithm shown. DENV: dengue virus; CHIKV: chikungunya virus; ZIKV: Zika virus; PCR: polymerase chain reaction; NS1: non-structural protein 1; ELISA: enzyme-linked immunosorbent assay; IgM/IgG: immunoglobulin M/G.

enrol participants until such time as *Wolbachia* deployment commences in the late-release area, which will not be before 2021, i.e. enrolment can continue even when the target sample size is reached.

Power calculations. It is estimated that 88 test-positive cases plus four times as many controls will be sufficient to detect a 50% reduction in dengue incidence with 80% power. Thus, we set the target sample size as 100 test-positive dengue cases and expect that by including in the analysis all participants enrolled after *Wolbachia* is established in the early zone, there will be in excess of 400 test-negative controls for 100 test-positive cases. Although we expect the true effect of *Wolbachia* on dengue transmission may be greater than a 50% reduction, the observable reduction in effect is expected to be lower because individuals are likely to spend a substantial proportion of their time outside their release zone of residence. These sample size estimates are based on [standard formulae](#) for calculating sample size/power in a case control study. They align with the proposed approach for estimating the intervention effect.

Statistical analysis. The analyses described here will be performed on datasets of cases and controls defined firstly using the primary endpoint of virologically-confirmed dengue cases, and

then using the endpoints of virologically-confirmed chikungunya and Zika cases.

The intention-to-treat analysis will consider *Wolbachia* exposure as a binary classification based on residence in the early or late-release area. Residence will be defined as the primary place of residence during the 10 days prior to illness onset. The intervention effect will be estimated from an aggregate odds ratio (for data aggregated across all three *Wolbachia*-release zones within each study arm) comparing the exposure odds (residence in the *Wolbachia* early-release area) among test-positive cases versus test-negative controls. The null hypothesis is that the odds of residence in a *Wolbachia* early-release area is the same among test-positive cases as test-negative controls.

The per-protocol analysis will consider *Wolbachia* exposure as a quantitative index based on measured *Wolbachia* prevalence in local *Ae. aegypti* mosquitoes in the locations visited by the participant during the 10 days prior to illness onset, both within the case control area and in elsewhere in Medellín and Bello. The per-protocol analysis therefore allows for *Wolbachia* exposure to vary in a location over time, and also accounts for human mobility, in terms of the exposure-time that individuals spend outside their area of residence as reported in the travel history

interview at enrolment. A weighted ‘*Wolbachia* exposure index’ (WEI) will be defined for each participant, as follows. The aggregate *Wolbachia* prevalence for each release zone will be calculated each month from all *Ae. aegypti* trapped in that zone. Time spent outside a *Wolbachia* release area will be treated as not *Wolbachia* exposed. The WEI for each participant will then be calculated by multiplying the zone-level *Wolbachia* prevalence (in the month of participant enrolment) at each of the locations visited, by the proportion of time spent at each location, to give a value on a continuous scale from 0 to 1.

An additional per-protocol analysis will be conducted in which the WEI is calculated using only the zone-level *Wolbachia* prevalence in the participant’s cluster of residence (in the month of participant enrolment), ignoring the participant’s recent travel history. This recognises that dengue exposure risk may be higher at home versus other locations, rather than assuming an even distribution of exposure risk across daytime hours and locations visited.

Cases and controls will be classified by strata of their WEI (e.g. 0-0.2; 0.2-0.4; 0.4-0.6; 0.6-0.8; 0.8-1). This acknowledges that the WEI is not a highly precise measure and serves to reduce error in exposure classification. This analysis can also account for the temporal matching of arboviral disease cases and test-negative controls: risk sets of cases and controls will be defined by frequency matching enrolled confirmed arboviral disease cases to arbovirus-negative controls with illness onset in the same quarter of the year. In the unlikely event that a minimum of four controls cannot be found for a case within the same quarter, the window for matching can be extended until four controls are identified, for that case only. For a time-adjusted analysis, a Cox proportional hazard model will be fitted, which can incorporate the temporal case-control risk sets and participants’ WEI stratum as a categorical variable, using time since completion of *Wolbachia* releases as the time scale.

Data management. Clinical study data will be stored in a custom designed relational database hosted on a secure web-based server. Role-based, tiered access permissions will be used to control access to the clinical database and associated data capture applications. User logs will document the activities of all users. An audit trail will be preserved within the database to capture the history of any changes made to data records after their initial capture.

Data collected from participants in the case-control study will be captured through standardised electronic data capture forms and digital mapping interfaces, deployed as web-based applications on mobile tablets. Laboratory diagnostic results will be captured directly from laboratory assay output and uploaded to a web-based application for storage in the same relational database. Validity controls will be applied at the point of data capture into electronic forms, by predefining value ranges, specifying categorical option lists, and minimizing the use of free text fields. The use of carefully designed electronic forms will facilitate the coding of participant responses at the point of data collection.

Quality control in the form of logic and consistency checks will be applied at the point of data capture into an electronic form and at the point of upload into the web-based database. All data relating to the case-control study, including field entomology and epidemiological data, will be retained indefinitely, and for a minimum of five years after study completion, in accordance with International Council for Harmonization on Good Clinical Practice requirements.

Monitoring of adverse events. Any severe adverse events (SAE) associated with collection of blood samples from study participants will be reported to the relevant institutional ethics committees within three days of notification. Standard SAE reporting forms will be used.

Study governance. A steering committee will be assembled to provide operational and strategic advice on planning and operations of the study. A WHO-convened independent evaluation group will review the study within a year of active enrolment as part of a program-wide evaluation of WMP Colombia activities in Medellín and Bello. The independent evaluation group will report its findings to all stakeholders at completion of the review.

Ethical considerations. The study protocol (version 3.0) and the informed consent document have been reviewed and approved by the Institutional Review Boards (IRBs) of the IPS Universitaria of Universidad de Antioquia, Colombia (No. 115, 25 Oct 2017 and No. 127, 12 Oct 2018), and Monash University, Melbourne (ID 11534). Any future protocol amendments will be submitted for review and approval by the same IRBs, prior to implementing protocol changes. The trial protocol was registered on ClinicalTrials.gov (NCT03631719) on 15th August 2018.

Confidentiality of participant information will be strictly maintained at all times by the participating investigators, research staff and the sponsoring institution (Universidad de Antioquia) by means of a coded ID number. This confidentiality is extended to cover testing of biological samples in addition to all laboratory specimens, reports, data collection forms and log books, and geolocated records relating to participating subjects. All records that contain names or other personal identifiers, such as informed consent forms, will be stored separately from study records while identified by ID numbers. All local databases will be secured with password-protected access systems. No information concerning the study or the data will be released to any unauthorised third party, without prior written approval of the sponsoring institution. Clinical or personal information will not be released without written permission of the subject, except as necessary for monitoring by an ethical review board or regulatory agencies. Reporting of study results will not be done in any way that permits identification of individual participants, or the location of their homes or other visited locations.

Current study status

Participant recruitment into the prospective case-control study commenced in early 2019 and is ongoing. *Wolbachia* deployments

across the two municipalities are ongoing through to 2020, and collation and analysis of disease surveillance data will continue until 2025.

Dissemination of study results

Analysis and reporting of the results of the prospective case-control study will occur only at completion of participant enrolment, and subject to the prior approval of the steering committee; there will be no interim analysis or dissemination of results. The interrupted time series analysis will be conducted 12 months after the completion of releases and annually thereafter. Findings from both studies will be submitted for peer review and publication in an appropriate open access journal, together with aggregate supporting data.

Discussion

Mosquito suppression remains the primary method used to control dengue virus transmission. A recent evaluation found little reliable evidence for the effectiveness of any dengue vector control method, and concluded that standardised studies of higher quality must be prioritised⁹. *Aedes aegypti* mosquitoes are the primary vectors of dengue, chikungunya and Zika viruses, therefore evidence-based interventions targeting this species have the potential to reduce multiple arboviral diseases where they co-circulate. The study described here will evaluate the impact of *Wolbachia*-infected mosquitoes on dengue and other arboviral diseases in Bello and Medellín municipalities, Colombia, using a combination of routinely collected disease surveillance data throughout the municipalities, and a prospective clinic-based test-negative study focused in one area of Medellín.

The test-negative design, a variant on the case-control design, which has been widely applied in non-randomised influenza vaccine effectiveness studies, uses outcome-based concurrent sampling of dengue cases and non-dengue controls to measure the efficacy endpoint^{23–26}. Effect estimates (odds ratios) from a test-negative design are equivalent to direct estimates of relative risk in the source population, under the assumption that the distribution of test-negative illness is not associated with the intervention, and that test-negative controls are allowed to include participants who may be classified as dengue cases at other times during the study period.

The interrupted time-series design is commonly used to evaluate the impact of public health interventions introduced at a population level and targeting population-level health outcomes^{27–29}. A series of repeat observations over time is analysed to establish a baseline trend which is assumed to be ‘interrupted’ by the introduction of an intervention. The subsequent post-intervention trend is compared to the counterfactual that would be expected in the absence of the intervention based on the baseline trend. A quantitative estimate of the intervention effect is derived from a segmented linear regression model of the outcome of interest (e.g. dengue case count or incidence) as a function of time, in which the intervention status is captured by a binary variable coded 0 for pre-intervention time points and 1 for post-intervention

time points^{30,31}. Seasonality and other secular trends (e.g. ENSO) and time-varying confounders can also be controlled for by the inclusion of additional model parameters. A limitation of using notifiable disease surveillance data is the imperfect specificity of the clinical case definition used for notifications, meaning an unknown and time-varying proportion of notified cases are not true dengue infections. Inconsistent reporting practices, outbreaks of non-dengue febrile diseases, or other factors may induce secular trends in the surveillance data that are independent of, but contemporaneous with, the *Wolbachia* intervention and thus may influence our ability to estimate the true intervention effect from time series data. A subset of the notified dengue cases in Colombia have supportive laboratory diagnostic results, but these have several limitations: i) laboratory testing can be infrequent, particularly during outbreaks, ii) the cross-reactivity of IgM serology between dengue and Zika limits the utility of serological data where Zika co-circulates, and iii) no virological confirmation (PCR or NS1 antigen detection) of cases is performed. We therefore base our primary analysis on all notified dengue cases (suspected and dengue IgM test positive). The benefits of using these routinely collected surveillance data include the availability of a long time series, reduced costs for data collection and timely acquisition of data.

The pragmatic approach described here to evaluate disease impact arose from the imperative from funders and local stakeholders to achieve rapid scale-up of *Wolbachia* deployments and to retain flexibility in the release sequence and methods, in the context of the declaration of the Zika public health emergency at the time of project conception and funding⁸. These imperatives precluded implementation of the proposed test-negative design study across all of Medellín/Bello, given the time required to obtain approvals, establish clinical enrolment processes, train staff, and then maintain an untreated comparison area for the duration of clinical enrolment. Randomised allocation of the early and late *Wolbachia* release areas in the focused case-control study was also not feasible, given the small number of zones within the case-control area. In general, there is greater potential for selection bias in non-randomised studies than in randomised studies, which, in the context of the current study, may present as a differential distribution of non-arboviral febrile illness (i.e. test-negative controls) by study arm due to chance imbalance in the care-seeking populations between study arms or differential propensity for care-seeking among those in areas where *Wolbachia* is released compared with untreated areas. As long as a core assumption of the test-negative design is met that the relative propensity to seek healthcare for undifferentiated febrile illness at a study clinic, in early vs late zones, is the same for dengue cases as for other febrile illness controls, then an imbalance in participant enrolment between early and late zones should not in itself bias the results.

A staged approach to city-wide deployments following a ‘stepped-wedge’ design was also considered in planning the disease impact assessment for Medellín, however this carried a requirement to define a deployment sequence that maintained balance

between ‘already treated’ and ‘not yet treated’ areas in factors associated with baseline dengue risk, to avoid selection bias. This had resource implications for the field entomology and community engagement teams’ activities that were inconsistent with the necessarily pragmatic approach to deployment in Medellín and Bello needed to achieve large-scale coverage within a short time frame.

The non-blinded deployment of the intervention means community members may alter their care seeking or vector control behaviour due to the belief that they are protected from dengue by *Wolbachia*. Blinding was determined to be cost prohibitive in this study as it would have doubled the resources and time required to conduct field releases of mosquitoes. Under the test-negative design, test-positive cases and test-negative controls are drawn from the same population of patients presenting to health clinics with febrile illness, who are clinically indistinguishable at the time of enrolment. Thus, the threat of bias due to non-blinding in the test-negative study is considered minimal as long as any modified behaviour applies equally to test-positive cases and test-negative controls. Routine vector control by health authorities were not altered as part of the study, and it is possible that some public health activities or change in community behaviour occurred which impacts arboviral disease incidence independently of *Wolbachia*, leading to an under- or over-estimation of the *Wolbachia* intervention effect in our study.

Contamination between adjacent *Wolbachia*-treated and untreated areas is a potential challenge in measuring the effectiveness of the *Wolbachia* intervention, and could theoretically arise from three sources: human mobility, mosquito movement, or spillover of the intervention effect due to broad suppression of dengue transmission. Given the highly focal nature of dengue transmission in urban settings^{32–34} it is unlikely, though possible, that interruption of dengue transmission in the *Wolbachia*-treated early-release area could suppress transmission also in the untreated late-release area. Human mobility may also confound the estimation of *Wolbachia*’s impact on arboviral disease, whereby individuals in whom the efficacy endpoint is measured may spend a proportion of their time outside their allocated study area (i.e. their area of primary residence) resulting in at least some exposure misclassification. There are no buffer zones separating the early-release and late-release areas of the case control study, nor the other areas of Medellín and Bello where staged deployments will occur, and *Wolbachia* spread from one area to another is possible but also measurable. The combined result of human mobility, *Wolbachia* contamination and any spillover effect is that the exposure status of the populations in the nominally ‘treated’ and ‘untreated’ areas become more similar to each other, thereby diluting any estimated intervention effect towards the null. By powering the case-control study to detect a relatively conservative effect size of 50%, we have allowed for some of this effect dilution while targeting a reduction in dengue incidence of public health significance. The case-control study per-protocol analysis, where recent travel history is documented and a

quantitative *Wolbachia* exposure status is calculated for each participant, will account for both for the time spent in areas away from home and the local measure of *Wolbachia* prevalence in visited areas.

Inter-annual fluctuations in dengue transmission mean that the case-control study might fall in a period of lower incidence just by chance. Nevertheless, the target sample size of 100 dengue test-positive cases is seen as feasible even in the event of a low transmission period. The interrupted time-series analysis, which spans a longer period than the case-control study, is expected to have at least three to five years of post-*Wolbachia* release data, and thus should be more tolerant to periods of low dengue transmission.

The generalisability of the current study’s findings to other dengue endemic settings will likely be influenced by setting-specific factors such as the local entomological and climate context, which influences *Wolbachia* introgression. Generalisability may also depend on the local distribution of circulating DENV serotypes and the intensity of virus transmission, which might influence the observed impact of *Wolbachia* on arboviral disease incidence. A cost-effectiveness analysis is underway in Indonesia, and the findings are expected to help inform cost optimisation for different deployment scenarios, target settings, and scale-up methods that can be applied to other countries. If the results of the current study do demonstrate a reduction in arboviral disease incidence associated with *Wolbachia* deployment in Medellín and Bello, a key next step would be to scale this intervention into wider public health implementation in Colombia and elsewhere in the Latin American region, using epidemiological, ecological and cost-effectiveness data to inform an optimal strategy for scaled deployment.

Ethics approval and consent to participate

This study has been approved by the Institutional Review Boards of the IPS Universitaria of Universidad de Antioquia, Colombia, and Monash University, Melbourne. Written informed consent will be obtained from all participants, or their guardian where the participant is a minor (<18 years), prior to enrolment in the clinic-based case-control study. The interrupted time-series analysis uses pre-existing non-identifiable disease surveillance data, which does not require individuals’ consent.

Data availability

No data is associated with this article.

Acknowledgements

The authors acknowledge the contributions of Peter Ryan (World Mosquito Program) for the planning and implementation of *Wolbachia* deployments in Medellín and Bello, Tomas Santamaria (World Mosquito Program) for administrative support, and Rita Almanza and Carlos Montes (Medellín Health Secretariat) for support and provision of Medellín surveillance data.

References

1. World Health Organisation: **Global strategy for dengue prevention and control 2012–2020**. Geneva: WHO; 2012.
[Reference Source](#)
2. Stanaway JD, Shepard DS, Undurraga EA, *et al.*: **The global burden of dengue: an analysis from the Global Burden of Disease Study 2013**. *Lancet Infect Dis*. 2016; **16**(6): 712–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Rolph MS, Foo SS, Mahalingam S: **Emergent chikungunya virus and arthritis in the Americas**. *Lancet Infect Dis*. 2015; **15**(9): 1007–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Weaver SC, Costa F, Garcia-Blanco MA, *et al.*: **Zika virus: History, emergence, biology, and prospects for control**. *Antiviral Res*. 2016; **130**: 69–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. World Health Organisation: **Outcome of the Emergency Committee regarding clusters of microcephaly and Guillain-Barre syndrome**. 2016; Accessed 2 May 2018.
[Reference Source](#)
6. World Health Organisation: **WHO Global Advisory Committee on Vaccine Safety Statement on Dengvaxia (CYD-TDV)**. 2017; Accessed 2 May 2018.
[Reference Source](#)
7. World Health Organisation: **Revised SAGE recommendations on use of dengue vaccine**. 2018; Accessed 2 May 2018.
[Reference Source](#)
8. World Health Organisation: **Mosquito (vector) control emergency response and preparedness for Zika virus**. 2016; Accessed 2 May 2018.
[Reference Source](#)
9. Bowman LR, Donegan S, McCall PJ: **Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis**. *PLoS Negl Trop Dis*. 2016; **10**(3): e0004551.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Wilson AL, Boelaert M, Kleinschmidt I, *et al.*: **Evidence-based vector control? Improving the quality of vector control trials**. *Trends Parasitol*. 2015; **31**(8): 380–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Hilgenboecker K, Hammerstein P, Schlattmann P, *et al.*: **How many species are infected with *Wolbachia*?—A statistical analysis of current data**. *FEMS Microbiol Lett*. 2008; **281**(2): 215–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. O'Neill SL, Pettigrew MM, Sinkins SP, *et al.*: **In vitro cultivation of *Wolbachia pipientis* in an *Aedes albopictus* cell line**. *Insect Mol Biol*. 1997; **6**(1): 33–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Rousset F, Vautrin D, Solignac M: **Molecular identification of *Wolbachia*, the agent of cytoplasmic incompatibility in *Drosophila simulans*, and variability in relation with host mitochondrial types**. *Proc Biol Sci*. 1992; **247**(1320): 163–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Stouthamer R, Breeuwer JA, Hurst GD: ***Wolbachia pipientis*: microbial manipulator of arthropod reproduction**. *Annu Rev Microbiol*. 1999; **53**: 71–102.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Dutra HL, Rocha MN, Dias FB, *et al.*: ***Wolbachia* Blocks Currently Circulating Zika Virus Isolates in Brazilian *Aedes aegypti* Mosquitoes**. *Cell Host Microbe*. 2016; **19**(6): 771–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Johnson KN: **The Impact of *Wolbachia* on Virus Infection in Mosquitoes**. *Viruses*. 2015; **7**(11): 5705–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Rainey SM, Shah P, Kohl A, *et al.*: **Understanding the *Wolbachia*-mediated inhibition of arboviruses in mosquitoes: progress and challenges**. *J Gen Virol*. 2014; **95**(Pt 3): 517–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Ferguson NM, Kien DT, Clapham H, *et al.*: **Modeling the impact on virus transmission of *Wolbachia*-mediated blocking of dengue virus infection of *Aedes aegypti***. *Sci Transl Med*. 2015; **7**(279): 279ra37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Villar LA, Rojas DP, Besada-Lombana S, *et al.*: **Epidemiological trends of dengue disease in Colombia (2000–2011): a systematic review**. *PLoS Negl Trop Dis*. 2015; **9**(3): e0003499.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Martinez M, Gomez S: **Chikungunya en Colombia, el inicio de la transmisión autóctona, 2014**. *IQUN*. 2014; **19**(18): 260–79.
[Reference Source](#)
21. National Health Institute: **Chikungunya Public Health Surveillance Protocol**. 2017; Accessed 5 Nov 2018.
[Reference Source](#)
22. National Health Institute: **Zika Public Health Surveillance Protocol**. 2017; Accessed 5 Nov 2018.
[Reference Source](#)
23. De Serres G, Skowronski DM, Wu XW, *et al.*: **The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials**. *Euro Surveill*. 2013; **18**(37): pii: 20585.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Foppa IM, Haber M, Ferdinands JM, *et al.*: **The case test-negative design for studies of the effectiveness of influenza vaccine**. *Vaccine*. 2013; **31**(30): 3104–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Jackson ML, Nelson JC: **The test-negative design for estimating influenza vaccine effectiveness**. *Vaccine*. 2013; **31**(17): 2165–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Orenstein EW, De Serres G, Haber MJ, *et al.*: **Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness**. *Int J Epidemiol*. 2007; **36**(3): 623–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Bernal JL, Cummins S, Gasparrini A: **Interrupted time series regression for the evaluation of public health interventions: a tutorial**. *Int J Epidemiol*. 2017; **46**(1): 348–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Gasparrini A, Gorini G, Barchielli A: **On the relationship between smoking bans and incidence of acute myocardial infarction**. *Eur J Epidemiol*. 2009; **24**(10): 597–602.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Steinbach R, Perkins C, Tompson L, *et al.*: **The effect of reduced street lighting on road casualties and crime in England and Wales: controlled interrupted time series analysis**. *J Epidemiol Community Health*. 2015; **69**(11): 1118–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Linden A: **Conducting interrupted time-series analysis for single- and multiple-group comparisons**. *Stata J*. 2015; **15**(2): 480–500.
[Publisher Full Text](#)
31. Lagarde M: **How to do (or not to do) ... Assessing the impact of a policy change with routine longitudinal data**. *Health Policy Plan*. 2012; **27**(1): 76–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Morrison AC, Minnick SL, Rocha C, *et al.*: **Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission**. *PLoS Negl Trop Dis*. 2010; **4**(5): e670.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Hoang Quoc C, Henrik S, Isabel RB, *et al.*: **Synchrony of Dengue Incidence in Ho Chi Minh City and Bangkok**. *PLoS Negl Trop Dis*. 2016; **10**(12): e0005188.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Salje H, Lessler J, Endy TP, *et al.*: **Revealing the microscale spatial signature of dengue transmission and immunity in an urban population**. *Proc Natl Acad Sci U S A*. 2012; **109**(24): 9535–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 01 December 2021

<https://doi.org/10.5256/f1000research.26341.r100109>

© 2021 Morrison A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amy Morrison

Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis (UC Davis), Davis, CA, USA

The revised study protocol “The impact of city-wide deployment of *Wolbachia*-carrying mosquitoes on arboviral disease incidence in Medellín and Bello, Colombia: study protocol for an interrupted time-series analysis and a test-negative design study” describes a pragmatic study designed to evaluate the impact of releases of *Aedes aegypti* stably transfected with the *Wolbachia* bacterium on the incidence of three *Aedes* transmitted viral diseases (ATVDs - dengue [DENV], chikungunya [CHIKV], and Zika [ZIKV]). There is and has been a critical need for evidence of Public Health Impact for vector-borne diseases for both traditional and novel vector control strategies. The *Wolbachia* releases described herein fall in the later category and the World Mosquito Program (WMP) continues to publish studies that indicate that this strategy has significant promise for controlling ATVDs in certain locations and ecologies. Although the authors provide a convincing argument for why they were unable to conduct a more rigorous randomized control trial design in this site. Because a cRCT is underway in Brazil and randomized control trial that also used the same test-negative design in Indonesia are providing high-level evidence that this vector control strategy is effective, I am supportive of developing alternative kinds of evidence which this study does (Utarini *et al.* (2021¹)). I can personally attest to the huge difficulties associated with carrying out and properly powering a cRCT for ATVDs, so the group's effort to develop more a pragmatic approach is a valuable contribution to the field. I would encourage the authors to suggest their study design for ongoing evaluations of traditional and novel vector control being deployed by government programs. When taking a pragmatic approach such as this using multiple approaches is far more credible than a single approach (test-negative case control study and interrupted time series analyses here). A third source of evidence that would have been even more convincing would have been a pediatric cohort in each of the 4 zones to measure seroconversion to ATVDs, preferably in a population who was seronegative at baseline. I would argue that it might provide a faster less bias estimate of the impact of *Wolbachia* releases on transmission between the two allocation areas. To be clear, the approach and study design is reasonable, especially if the 4 zones are comparable, which the authors indicate they are. I would however ask that the authors address the following critical questions.

Are other vector control activities being conducted during the pre- and post- release periods? How do these activities potentially impact the interpretation of both the interrupted time series and test-negative test? I think it is important to provide some evidence that these government measures, effective or not, are applied equally across the 4 zones used for the test-negative study and that any impact observed in the interrupted time series analysis is not due to ongoing activities especially if government programs have improved since releases began. My suspicions are these arguments can be made but controlling for or at least considering these activities should be addressed in the article.

The article/protocol focuses on the human component of the study which is appropriate, however, more details on the release strategy and approach would provide a more complete picture. The most important issue here is *Wolbachia* prevalence. I think this document would benefit from a clear description of the minimum *Wolbachia* prevalence required by the design and the range (expected variation) of prevalence expected. Although an earlier release in which *Wolbachia* did not become established is mentioned, the implications of this are important. What happens if *Wolbachia* does not become established in any of the negative test zones?

I have some concerns about the WEI. From a theoretical perspective this looks great, but inclusion (as an appendix) of the human mobility survey would be helpful. In my experience it takes considerable effort to confirm all secondary locations and to estimated time in the two allocation arms will be quite variable over the 10-day period. I commend the authors for attempting to account for the fact that participants will not always be in a "protected" area and can be exposed to ATVDs outside of the zone of their primary residence. More details on this questionnaire would be appreciated. Additionally, how missing, or incomplete data is handled here would be useful. You are really asking what proportion of time is spent in study zone versus outside it, and if outside means an untreated area or not..

Although I do not think I was able to access the full written responses to the previous reviewers, the current version does address most of the issues raised. It also provides a discussion of many of the design limitations, of which there are many. I say that not as a criticism, because it is widely accepted that surveillance programs are severely flawed, presenting a variety of challenges to proper evaluation of disease endpoints. If the results from the proposed study are viewed carefully, and the final analyses clearly described without bias, this study will provide important data on the efficacy of *Wolbachia* releases. The statistical analysis presented in this article, has a lot of built in flexibility, which I'm not opposed to, however, this does open the authors up to criticism for what might look like data massaging or selecting the approach that will look most favorable. The details of the per protocol analysis will need to be disclosed in detail when the studies are published.

Below are some specific comments and observations from the text:

- **Background:**
 - Paragraph 4: The sentence, "The mean annual incidence of notified dengue cases in the seven years 2010–2016 prior to the start of scaled *Wolbachia* deployments was 298 per 100,000 population in Medellin (range 38 – 771 per 100,000) and 188 per 100,000 population in Bello (range 36 – 446 per 100,000)", is duplicated. Eliminate the first which also includes a typo.

- Table 1. Could information also be stratified by allocation. This table could be structured differently to provide both the aggregated, allocation-specific data, and the 4 zones selected for the study.
- **Laboratory Investigations:**
 - I would be more comfortable if paired acute and convalescent samples could have been collected here. If the inclusion criteria are applied consistently across the same zones and overtime, I believe you are detecting a real signal here but there is the potential for misclassification of true dengue cases as negative controls. The exclusion of the equivocal and dengue IgM/IgG ELISA positive will reduce this possibility but reporting how many of these individuals are excluded should be done when reporting the final study results.
 - I would have liked to see a contingency for situations with confirmed CHIKV/ZIKV outbreaks. That is define criteria, when added CHIKV/ZIKV testing would be done. Again, your approach is consistent and still identify signal differences between the two allocation arms, but with ZIKV the time window to detect acute infections by PCR can be short. I would only suggest this during periods of high and known transmission which I assume have not been detected during the follow up period yet.
- **Expected study duration:** Will deployment in the late release areas be delayed if the target sample size is not reached?
- **Correct typo below:** "The study will continue to enrol participants until such time as *Wolbachia* deployment commences in the late-release area".
- **Statistical Analysis Plan:** Calculation of the WEI: From a theoretical perspective this looks great, but inclusion of the human mobility survey would be useful. Also, in my experience it takes considerable effort to confirm all secondary locations and estimating time in the two allocation arms will be quite variable over the 10-day period.
- **Monitoring of adverse events:** Do you expect any Severe Adverse Events? What are they and how would you monitor for them? Will you have any contact with participants after they provide the blood sample. Do you provide results. Clearly this is standard language, but it would be more appropriate the indicate what adverse events are expected and what would constitute and Severe Adverse Event in the context of the study. For example, would a participant who develops severe dengue, becomes hospitalized, and needs ICU care be reported in this context?
- **Ethical considerations:** Is there any national or government approvals required and if so, what? This study is clinical research but a clinical trial.

References

1. Utarini A, Indriani C, Ahmad R, Tantowijoyo W, et al.: Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue. *New England Journal of Medicine*. 2021; **384** (23): 2177-2186
[Publisher Full Text](#)

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Partly

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: I was part of an external evaluation group that evaluated the WMP project in Bello and Medellin in 2019.

Reviewer Expertise: I have conducted prospective epidemiological studies on dengue and its vector *Aedes aegypti* in the city of Iquitos, Peru since 1998. I have conducted two cRCTs with epidemiological endpoints for insecticide treated curtains and spatial repellents against ATVDs as well as other vector control trials

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 11 June 2021

<https://doi.org/10.5256/f1000research.26341.r63750>

© 2021 Waterman S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stephen Waterman

CDC Dengue Branch, Centers for Disease Control and Prevention (CDC), San Juan, Puerto Rico

This manuscript describing the protocol for a intervention trial of *Wolbachia* replacement in *Aedes aegypti* populations with the wMel *Wolbachia* strain to prevent dengue, Zika and chikungunya in the complicated densely populated urban environments of Rio de Janeiro and Niteroi, Brazil, has been revised somewhat in response to previous open reviewers. In response to both reviewers, the authors explain the pragmatic reasoning behind not conducting the study as a cluster randomized trial. In addition to community pressure to deploy the intervention quickly and in wide areas as a result of the Zika outbreak, the authors indicate that the necessary community engagement to set up clusters was not feasible given the resources available, and that the smaller geographic units are more susceptible to contamination. In response to reviewer 1 the authors clarify the *Wolbachia* strain used and state that the wMel strain has persisted at high levels for over two years in Indonesia and as many 8 years in northern Australia.

Each city has four intervention release zones (ranging from 9 to 51 square kms and populations densities from 1,400-18,000 persons/square km) and a large non-release control area. Adult mosquito releases took place between late 2015 and the end of 2019 and lasted for at least 16 weeks in each release zone. *Wolbachia* introgression frequency monitoring is done with BG traps and PCR testing of a sample of the mosquitoes collected. The study design main analysis methodology is controlled interrupted time series which makes use of routinely collected public health disease surveillance data and requires that consistent historical data is available supporting the comparability of the intervention and control areas. The analysis compares the incidence of suspect and confirmed dengue cases before and after the intervention in the treatment and control zones. Additional details on the regression analysis have been provided. Power estimates from simulations based on binomial distribution of ten year historical data suggest that the study has 80% to detect a 50% reduction after three years, and a 60% reduction after two years.

This study is important to assess the impact of *Wolbachia* replacement in a highly *Aedes aegypti* transmitted disease endemic urban area in Latin America, as the other studies conducted by the World Mosquito Program have been done in Asia or in non-endemic Australia. Since the study is not randomized, including as much detail as possible in the description of the methods and the results in eventual publications will be important to assess the strengths and weaknesses of the study.

Comments:

- Additional details regarding the *Wolbachia* mosquito releases and trapping results would be of interest. Why were releases done as adult mosquito releases and not eggs as in the Yogyakarta Indonesia RCT trial? (Anders *et al.* (2020¹)) Were releases in all release zones begun simultaneously or staggered? Were the BG trap adult female *Aedes aegypti* mosquito counts/densities comparable in the different zones and control area? Will the study design enable assessment of the impact of *Wolbachia* releases on *Aedes* species abundance?
- Large dengue outbreaks had not occurred prior to the intervention in the study cities since 2013. Is there available seroprevalence data for dengue and Zika in the intervention zones and the control area prior to the wMel intervention? Do we know if pre-intervention reported Zika incidence in 2016 was comparable in the intervention and control areas?
- The analysis plan is to report results two years after completion of releases. If the releases were staggered will the initial publication include data from all the intervention zones?
- Are the secondary endpoint analyses of severe dengue cases and fatalities intended to strengthen the efficacy evidence with data on confirmed diagnoses, to help address the cost effectiveness of the intervention, or to address a question whether *Wolbachia* reduces the severity of disease when transmission does occur?
- The protocol states that the study will continue through 2023 and analyses will be done each year for 5 years. Since the releases finished at the end of 2019, will an analysis of the sustained *Wolbachia* introgression and cumulative epidemiologic impact after 5 years be possible?

Minor comments:

- The statement in last paragraph of page 9 that we have no evidence of dengue, Zika or

chikungunya transmission where high levels of *Wolbachia* have been established is somewhat misleading in that the authors are referring to northern Australia where *Aedes aegypti* transmitted diseases are not endemic and the force of infection is considerably lower than Asia and Latin America.

- The comment on page 9, next to last paragraph with regard to the licensed CYD-TDV vaccine being rendered less feasible in high burden areas because of the need for pre-vaccination screening actually better applies to low burden areas. WHO included in its 2018 vaccine recommendations (WHO (2018²)) that areas with dengue seroprevalence of 80% or greater in 9 years might consider forgoing pre-vaccination screening. In low burden regions the risk of vaccinating false serologic positives increases and the cost effectiveness decreases. The authors may want to clarify whether they think *Wolbachia* replacement could make dengue vaccines unnecessary.

References

1. Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, et al.: Update to the AWED (Applying Wolbachia to Eliminate Dengue) trial study protocol: a cluster randomised controlled trial in Yogyakarta, Indonesia. *Trials*. 2020; **21** (1): 429 [PubMed Abstract](#) | [Publisher Full Text](#)
2. WHO: Weekly epidemiological record, No 36, 7 September. 2018. [Reference Source](#)

Is the rationale for, and objectives of, the study clearly described?

Not applicable

Is the study design appropriate for the research question?

Not applicable

Are sufficient details of the methods provided to allow replication by others?

Not applicable

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology, dengue and arbovirology, tropical medicine

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 16 December 2019

<https://doi.org/10.5256/f1000research.21786.r57177>

© 2019 Hancock P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Penelope Hancock

Big Data Institute, University of Oxford, Oxford, UK

The paper describes protocols for assessing the efficacy of *Wolbachia* releases on reducing dengue incidence based on data from release trials conducted in municipalities in Columbia. The *Wolbachia* has been released into 6 adjacent zones covering a sub-area, where 3 of the zones have early releases and the other 3 have later releases – the zones which receive late releases are regarded as non-intervention arms for the purposes of the trial analysis.

It is always difficult to measure the efficacy of vector control interventions using randomized trials because of community level effects such as herd immunity, so that the intervention has impacts on both treatments and controls, and the estimated effect of the intervention is diluted – an effect known as contamination. In the case of *Wolbachia* releases, the effect is particularly difficult to quantify because the *Wolbachia* may spread to mosquito populations in the control arms, or *Wolbachia* may only have an intermediate (and variable) prevalence in the intervention arms. The trial described in this paper has additional complications which the authors describe in the manuscript, including the non-random allocation of intervention clusters and the small size of the study area with intervention arms adjacent to control arms and no buffer between them. The authors explain that these limitations mean that a pragmatic approach to analysis of *Wolbachia* efficacy is required.

I think the paper would benefit from a more rigorous quantitative protocol for how intervention efficacy can be quantified in the presence of contamination (see Silkey *et al.* 2016, [Trials](#)¹). The power calculation that the authors provide doesn't explore impacts of contamination, or impacts of incomplete spread of *Wolbachia* in the intervention arm. In addition the issue of herd immunity should be pointed out in the paper. It seems that given the configuration of the release zones, an effective *Wolbachia* intervention could greatly interrupt dengue transmission in the non-intervention (later release zones) as well, thus making efficacy very difficult to evaluate.

I find the *Wolbachia* Exposure Index proposed for individual participants (to account for their movements outside/into release zones) to be problematic. *Aedes aegypti* have a very heterogeneous local distribution, and I don't think variations in exposure can be calculated using travel histories – these estimates are likely to be misleading at best.

Regarding the interrupted time series approach, I think a more detailed and formal mathematical description of the method is needed, detailing the sampling distribution of the infection data with respect to the location of *Wolbachia* interventions, and the statistical model for handling spatiotemporal autocorrelation. It does not seem straightforward to distinguish the effect of *Wolbachia* from non-related fluctuations in disease incidence caused by environmental factors. More explanation of how this will be achieved is required.

Please put a scale on the map in Figure 1.

References

1. Silkey M, Homan T, Maire N, Hiscox A, et al.: Design of trials for interrupting the transmission of endemic pathogens. *Trials*. 2016; **17** (1). [Publisher Full Text](#)

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Partly

Are sufficient details of the methods provided to allow replication by others?

No

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Spatial modelling and statistics, population dynamics, *Wolbachia*.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 13 May 2020

Katherine ANDERS, Monash University, Melbourne, Australia

I think the paper would benefit from a more rigorous quantitative protocol for how intervention efficacy can be quantified in the presence of contamination (see Silkey et al. 2016, Trials).

Authors' response:

Contamination will be addressed in the analysis by incorporating area-level measured *Wolbachia* frequencies in the model, rather than presuming an area's exposure status based on whether *Wolbachia* releases had occurred in that area. For the interrupted time-series analysis of dengue cases notified to the Medellin and Bello health surveillance system, additional analyses will now explore the effect of *Wolbachia* on the incidence of notified dengue using *Wolbachia* frequency either as a continuous covariate or categorised into quintiles of exposure. In the per-protocol analysis of the case-control study, each participant will be assigned a *Wolbachia* Exposure Index calculated using zone-level *Wolbachia* frequency and time spent in that release zone. These methods thus additionally take into account potential incomplete spread of *Wolbachia* in release areas as well as contamination into areas where *Wolbachia* releases have not yet occurred.

The method proposed by Silkey *et al* to quantify the magnitude of the contamination effect – i.e. comparing disease incidence among naïve (non-intervened) groups living close to an intervention area to those in naïve groups living remote from the intervention - cannot

account for the possibility that *Wolbachia* fails to establish in a communa where releases have occurred and would instead assume these comunas to be *Wolbachia*-treated.

The power calculation that the authors provide doesn't explore impacts of contamination, or impacts of incomplete spread of Wolbachia in the intervention arm.

Authors' response:

Contamination and/or incomplete spread of *Wolbachia* is expected to dilute any intervention effect by making the intervention and untreated areas more similar. Our sample size is powered to detect the conservative effect size of 50%, though we expect the true reduction in dengue incidence to be much greater than 50% based on preliminary findings from other WMP project sites which demonstrate reductions ranging from 75% to 97% at 12 months or more post-intervention. Our existing sample size therefore allows for a dilution of the true intervention effect by contamination, incomplete *Wolbachia* establishment in intervention areas, and/or human mobility.

In addition the issue of herd immunity should be pointed out in the paper. It seems that given the configuration of the release zones, an effective Wolbachia intervention could greatly interrupt dengue transmission in the non-intervention (later release zones) as well, thus making efficacy very difficult to evaluate.

Authors' response:

Dengue transmission is known to be quite focal (<500m) in urban areas (Salje et al PNAS 2012; Morrison et al PLoS NTD 2010) so it is unlikely, although possible, that interruption of transmission in the early release zone would have spillover effects into the adjacent late release areas, independent of the potential movement of the *Wolbachia* mosquitoes themselves. A brief discussion has been added to the paper (see Discussion, paragraph 7).

I find the Wolbachia Exposure Index proposed for individual participants (to account for their movements outside/into release zones) to be problematic. Aedes aegypti have a very heterogeneous local distribution, and I don't think variations in exposure can be calculated using travel histories – these estimates are likely to be misleading at best.

Authors' response:

The *Wolbachia* Exposure Index aims to capture not only human mobility in and out of release zones, but also heterogeneity in *Wolbachia* establishment among the early-release zones. The WEI will be calculated using the zone-specific aggregated *Wolbachia* prevalence in the month of participant enrolment, which recognises that *Wolbachia* establishment in intervention areas may be imperfect, that some *Wolbachia* spread into the control area may occur, and that *Wolbachia* prevalence varies across time. We acknowledge that there will be heterogeneity in *Wolbachia* frequency even within each zone (and also in *Ae. aegypti* distribution as the reviewer notes), however, no accurate interpolation at a geographical scale smaller than communa level is possible.

We have added an additional per-protocol analysis in which the WEI is calculated using only the zone-level *Wolbachia* prevalence in the participant's zone of residence (in the month of participant enrolment), ignoring the participant's recent travel history. This recognises that

dengue exposure risk may be higher at home versus other locations, rather than assuming an even distribution of exposure risk across daytime hours and locations visited (see paragraph 4 of Methods – Statistical analysis).

Regarding the interrupted time series approach, I think a more detailed and formal mathematical description of the method is needed, detailing the sampling distribution of the infection data with respect to the location of Wolbachia interventions, and the statistical model for handling spatiotemporal autocorrelation. It does not seem straightforward to distinguish the effect of Wolbachia from non-related fluctuations in disease incidence caused by environmental factors. More explanation of how this will be achieved is required.

Authors' response:

We previously planned on using a mixed-effects negative binomial model to assess the impact of the *Wolbachia* intervention on dengue incidence, modelling between-communa variability as a random effect by including a random intercept at the communa level and allowing for a random-slope on the intervention. However, given that modelling the random effects themselves are not of particular interest in this analysis, it was decided that a generalised estimating equation approach would be more efficient as it most directly targets the group-level parameter of the intervention effect and requires fewer modelling assumptions than a mixed-effects model. The outcome distribution is assumed to be negative binomial to allow for overdispersion. Monthly case counts will be modelled as the outcome variable, with an offset for population size and controlling for seasonality using flexible cubic splines. Robust standard errors will be used to account for clustering of cases by communa. An autoregressive correlation structure will be specified to account for temporal autocorrelation. A mixed-effects model will then be used to check for potential small sample issues in inference estimation, given the modest number of clusters in Medellin (18 comunas) and Bello (11 comunas) and the large number of observations per cluster.

We acknowledge that there may be other environmental factors contributing to natural fluctuations in dengue incidence which we are unable to explicitly account for in the model. The availability of historical data (range 5-8 years) and the staged nature of the intervention means the statistical model includes between-communa (within-period) comparisons as well as before-and-after (within-communa) comparisons, which is expected to control for at least some of these natural fluctuations that are unrelated to the *Wolbachia* intervention.

Please put a scale on the map in Figure 1.

Authors' response:

A scale has been added to the map.

Competing Interests: None

<https://doi.org/10.5256/f1000research.21786.r51965>

© 2019 Waterman S et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stephen Waterman

CDC Dengue Branch, Centers for Disease Control and Prevention (CDC), San Juan, Puerto Rico

Roberto Barrera

CDC Dengue Branch, Centers for Disease Control and Prevention (CDC), San Juan, Puerto Rico

This paper describes the protocol for a clinical trial releasing *Wolbachia* bacterium infected male and female *Aedes aegypti* mosquitoes in Medellín and Bello, Colombia, with the primary endpoint objective of demonstrating reduction of human dengue infections in the population living in the treated areas. *Wolbachia* infected female release over time results in replacement of the uninfected *Aedes aegypti* population with *Wolbachia* infected mosquitoes that have reduced ability to transmit arboviruses. The study design has two components, an interrupted time series (ITS) approach using passive arboviral disease surveillance data from Bello and a large area of Medellín, and a prospective case-control in a smaller area of northeast Medellín using arbovirus laboratory test negative acute febrile illness controls in 6 early release and late release zones. The studies begin approximately one year after mosquito releases (in 2018 for the early release zone and 2019 for the releases outside the case-control area) to allow for mosquito population replacement.

This study employs a novel *Aedes aegypti* vector control approach to address the major and growing tropical public health problem of *Aedes* transmitted arboviruses including dengue, Zika, and chikungunya viruses. The authors point out that such studies are badly needed as conventional *Aedes aegypti* vector control approaches have failed or been shown to be non-sustainable, and the only currently licensed dengue vaccine is partially effective and requires a laboratory test prior to immunization.

This study protocol builds on laboratory and fieldwork in Australia and elsewhere, and is well designed and well written with considerable detail (design, statistical power and analysis, laboratory testing, data management, etc) to address the question of human arboviral disease impact of *Wolbachia* replacement in a highly endemic tropical urban setting in Latin America. The protocol is intentionally “pragmatic” to roll out the intervention at large scale under operational conditions in a timely and cost effective manner acceptable to the study community. The authors thus effectively answer potential criticisms of the study design not being a cluster randomized clinical trial as recommended by the WHO Vector Control Advisory Group. The case control study design also importantly accounts for the extent of replacement with *Wolbachia* infected mosquitoes in the treated area and human mobility out of the treatment area with a calculated *Wolbachia* exposure index calculated for each acute febrile illness patient.

The test negative case control study design obviates the need for expensive clinical cohort follow up to monitor disease incidence and treated and untreated areas. The authors correctly point out that the risk estimate from the test negative case control approach is likely to be unbiased and can be used to calculate efficacy confidence limits. The ITS approach is a less rigorous experimental design in that the vast majority of passively reported cases are not virologically confirmed, and

surveillance may not be always be done in a consistent manner, but is another practical approach using available data from the Ministry of Health that allows for monitoring of reductions in arboviral case reports over a long time period (5 years) after the *Wolbachia* replacement treatment during which arbovirus outbreak cycles would be expected to occur.

The discussion appropriately comments on the potential generalizability of the findings to other settings and that cost effectiveness analysis of this approach is underway.

The following are suggestions to clarify aspects of the protocol:

Background:

1. While Medellín is clearly highly endemic for dengue, including the historical annual average incidence of dengue would be of interest, as the case-control study will be just be done over a one year time period. Dengue transmission dropped to unusually low levels throughout most of South America after the Zika epidemic, and is on the increase in the region as of mid-2019.

Methods:

1. The entomologic details regarding the mosquito releases and strain(s) of *Wolbachia* could be expanded upon. What is being done differently in 2018 and 2019 compared to the 2017 releases that achieved temporary high *Wolbachia* prevalence?
2. More details on the *Wolbachia* sampling and monitoring strategy would be helpful. What is the extent of the monitoring area? All comuna outside the case-control area? Checking BG traps once a week does not ensure that the mosquito specimens will be identified correctly because of damage from the trap fans to captured mosquitoes. Many samples will be lost because of loss of power, ants, etc. BG traps should be checked daily.
3. For the ITS component and the secondary endpoint of severe dengue incidence, how does the Ministry of Health define severe dengue, and has severe dengue been consistently defined over time?
4. Regarding the case control study participant recruitment, what is the possibility that patients with acute febrile illness in the study areas will seek care in clinics outside the network?
5. With regard to the laboratory testing algorithm to exclude potential dengue serologic positives from being control patients, the authors could more explicitly state that PanBio IgG ELISA test is designed with cutoffs to only detect high IgG titers consistent with acute secondary infections, and not past infections. Excluding all patients with IgG antibody due to past dengue infection in this setting would eliminate a large percentage of the potential control patients.
6. Consider observing changes in the vector-bacteria-virus interaction through time. Coevolution is likely. Whether virus blocking ability changes over time (e.g., lowered bacteria concentration in the mosquito cells) is not clear.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Partly

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology, dengue and arbovirology, tropical medicine

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 13 May 2020

Katherine ANDERS, Monash University, Melbourne, Australia

Background:

1. To clarify, the case-control study period was planned to be *a minimum* of 12 months duration but now has funding to continue in order to attain the target sample size, given the low dengue event rate throughout this region of Colombia following a large epidemic in 2016. We have removed the timeline in Figure 4, which is no longer applicable. We have now included the historical annual average incidence of dengue in Medellin and Bello in the background section, as suggested.

Methods:

1. Text has been added to the second paragraph under '*Wolbachia* deployment' to clarify the changes in *Wolbachia* release material from the 2017 to the 2018/2019 releases, as follows: 'An initial period of *Wolbachia* deployment was undertaken in the early-release zone of the case-control area and in parts of Bello between April and December 2017, resulting initially in a high prevalence of *Wolbachia*. However, *Wolbachia* levels declined after cessation of releases. We believe this was due to fitness issues with the *Wolbachia*-infected mosquitoes, specifically that they were less resistant to insecticides than the wild population. Insectary processes were subsequently updated and a new colony of *Wolbachia* mosquitoes was produced that matched the wildtype insecticide resistance profile. Subsequent rounds of deployments were then conducted in these areas between mid-2018 and late-2019. It is this deployment period that will be considered for the purpose of the analyses described in this protocol.'

2. The text describing the *Wolbachia* sampling and monitoring strategy has been edited to clarify that '*Wolbachia* prevalence is monitored through a network of BG-Sentinel adult mosquito traps (BioGents) that are evenly spaced throughout all of Bello and Medellin, including the case-control study area, at a density of approximately 16 BG traps per km²,

and that 'BG traps that do not catch any mosquitoes in three consecutive weeks are moved to another location'. Servicing BG traps more frequently than once a week is not feasible for city-wide projects, and weekly collection is standard across all our project sites. There is certainly the potential for loss of samples due to damage, predators, loss of power etc, but this would result only in a loss of sample size for estimation of *Wolbachia* prevalence, not a bias in these estimates. Trap failures for various reasons are noted at the time of trap servicing and documented in the entomological database.

3. The case definition for severe dengue has now been added to the text describing the primary and secondary endpoints for the ITS analysis, as follows:

'Severe dengue is defined as any case of dengue that has one or more of the following manifestations: i) shock or respiratory distress due to severe plasma leakage; ii) severe bleeding according to the evaluation of the treating physician; or iii) severe organ involvement, such as liver damage, impaired consciousness, myocarditis, or other organ involvement.'

4. We know that a subset of patients with acute febrile illness in the study areas certainly will seek care in clinics outside the network of study clinics, and indeed outside the case-control study area. However the test-negative case-control design is robust to this, based on the assumption that the propensity of patients from the treated and untreated case-control areas to seek care at the network of study clinics is equivalent among test-negative controls (patients with other causes of febrile illness) and test-positive dengue cases. Ie. complete sampling of acute febrile illness patients in the study area is not required, as long as the sampling fraction can be assumed to be equivalent for test-positive cases and test-negative controls.

5. This clarification has been added to the text describing methods for laboratory investigations.

6. Work is ongoing to monitor the co-evolution of *Wolbachia* and *Aegypti* over time in our Australian and international field sites. Preliminary unpublished WMP work has established that the wMel *Wolbachia* genome remains highly stable eight years post-release in northern Australia. Others have shown that pathogen blocking in *Wolbachia*-infected *Ae. aegypti* is stable due to an evolutionary trade off between the mosquito host and the bacteria (Ford et al (2019) *Nature Microbiology*), whereby mutations in *Ae. aegypti* that reduce *Wolbachia*-mediated virus blocking carry a significant fitness cost.

Competing Interests: None

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research